FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs18-p2-08-19 ◽

2019 ◽

Author(s):

MJ Wongchenko ◽

M Oliveira ◽

C Saura ◽

P Nuciforo ◽

I Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)

10.1158/1538-7445.am2018-ct041 ◽

2018 ◽

Cited By ~ 2

Author(s):

Mafalda Oliveira ◽

Cristina Saura ◽

Isabel Calvo ◽

Jay Andersen ◽

José Luis Passos Coelho ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)

10.1158/1538-7445.am2019-4891 ◽

2019 ◽

Author(s):

Zhen Shi ◽

Steven J. Isakoff ◽

Cristina Saura ◽

Paolo Nuciforo ◽

Isabel Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Phase Ii ◽

Gene Expression Analysis ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)

10.1158/1538-7445.sabcs18-4891 ◽

2019 ◽

Author(s):

Zhen Shi ◽

Steven J. Isakoff ◽

Cristina Saura ◽

Paolo Nuciforo ◽

Isabel Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Phase Ii ◽

Gene Expression Analysis ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract P2-16-01: A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC)

10.1158/0008-5472.sabcs13-p2-16-01 ◽

2013 ◽

Cited By ~ 5

Author(s):

V Dieras ◽

D Yardley ◽

G Romieu ◽

V Valero ◽

S Isakoff ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Controlled Trial ◽

Weekly Paclitaxel ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

Locally Recurrent

OT3-01-11: A Randomized, Phase II Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating MetMAb and/or Bevacizumab in Combination with Weekly Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-11 ◽

2011 ◽

Author(s):

BR Daniel ◽

M Campone ◽

V Dieras ◽

T Ervin ◽

W Yu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Controlled Trial ◽

Weekly Paclitaxel ◽

Double Blind ◽

Double Blind Placebo ◽

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1007 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1007-1007 ◽

Cited By ~ 34

Author(s):

Peter Schmid ◽

Jacinta Abraham ◽

Stephen Chan ◽

Duncan Wheatley ◽

Murray Brunt ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy

Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

10.1158/1538-7445.sabcs15-s6-07 ◽

2016 ◽

Cited By ~ 6

Author(s):

O Gluz ◽

U Nitz ◽

C Liedtke ◽

M Christgen ◽

K Sotlar ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Randomized phase II trial to evaluate the safety and efficacy of neoadjuvant cisplatin in combination with taxanes-anthracyclines vs taxanes-anthracyclines alone in locally advanced triple negative breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e12024 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e12024-e12024 ◽

Cited By ~ 7

Author(s):

Maria Cristina Aguilar Martinez ◽

Claudia Arce-Salinas ◽

Alberto Alvarado-Miranda ◽

Fernando Lara-Medina ◽

Diana flores-Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Locally Advanced ◽

Safety And Efficacy ◽

Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP)

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3646 ◽

2020 ◽

pp. clincanres.3646.2020

Author(s):

Priyanka Sharma ◽

Bruce F Kimler ◽

Anne P O'Dea ◽

Lauren Nye ◽

Yen Y Wang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Stage I ◽